Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial

Open access
Martin-Broto, Javier, Hindi, Nadia, Grignani, Giovanni, Martinez-Trufero, Javier, Redondo, Andres, Valverde, Claudia, Stacchiotti, Silvia, Lopez-Pousa, Antonio, D'Ambrosio, Lorenzo, Gutierrez, Antonio, Perez-Vega, Herminia, Encinas-Tobajas, Victor, de Alava, Enrique, Collini, Paola, Peña-Chilet, Maria, Dopazo, Joaquin, Carrasco-Garcia, Irene, Lopez-Alvarez, Maria, Moura, David S, Lopez-Martin, Jose A · 2020 · Journal for ImmunoTherapy of Cancer

Abstract

Background: Sarcomas exhibit low expression of factors related to immune response, which could explain the modest activity of PD-1 inhibitors. A potential strategy to convert a cold into an inflamed microenvironment lies on a combination therapy. As tumor angiogenesis promotes immunosuppression, we designed a phase Ib/II trial to test the double inhibition of angiogenesis (sunitinib) and PD-1/PD-L1 axis (nivolumab). Methods: This single-arm, phase Ib/II trial enrolled adult patients with selected subtypes of sarcoma. Phase Ib established two dose levels: level 0 with sunitinib 37.5 mg daily from day 1, plus nivolumab 3 mg/kg intravenously on day 15, and then every 2 weeks; and level −1 with sunitinib 37.5 mg on the first 14 days (induction) and then 25 mg per day plus nivolumab on the same schedule. The primary endpoint was to determine the recommended dose for phase II (phase I) and the 6-month progression-free survival rate, according to Response Evaluation Criteria in Solid Tumors 1.1 (phase II). Results: From May 2017 to April 2019, 68 patients were enrolled: 16 in phase Ib and 52 in phase II. The recommended dose of sunitinib for phase II was 37.5 mg as induction and then 25 mg in combination with nivolumab. After a median follow-up of 17 months (4–26), the 6-month progression-free survival rate was 48% (95% CI 41% to 55%). The most common grade 3–4 adverse events included transaminitis (17.3%) and neutropenia (11.5%). Conclusions: Sunitinib plus nivolumab is an active scheme with manageable toxicity in the treatment of selected patients with advanced soft tissue sarcoma, with almost half of patients free of progression at 6 months. Trial registration number NCT03277924 .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jitc-2020-001561

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 CONSORT diagram. CONSORT, Consolidated Standards of Reporting Trials; ECOG, Eastern Cooperative Oncology Group; RECIST, Response Evaluation Criteria in Solid Tumors.
Figure 1 CONSORT diagram. CONSORT, Consolidated Standards of Reporting Trials; ECOG, Eastern Cooperative Oncology Group; RECIST, Response Evaluation Criteria in Solid Tumors.CC BY-NC · PubMed Central
Figure 2 Response to treatment by patient according to RECIST. All evaluable patients (N=60) from phase Ib (n=14) and phase II (n=46) are shown. Tumor diameter was measured in millimeters. The dashed lines represent 20% increase in diameter and 30% decrease in diameter (RECIST progression and response cut-offs, respectively). *No size variation. RECIST, Response Evaluation Criteria in Solid Tumors.
Figure 2 Response to treatment by patient according to RECIST. All evaluable patients (N=60) from phase Ib (n=14) and phase II (n=46) are shown. Tumor diameter was measured in millimeters. The dashed lines represent 20% increase in diameter and 30% decrease in diameter (RECIST progression and response cut-offs, respectively). *No size variation. RECIST, Response Evaluation Criteria in Solid Tumors.CC BY-NC · PubMed Central
Figure 3 Progression-free survival to treatment by patient, based on RECIST central radiological assessment. Each patient in the efficacy population in phase II is represented as bars (n=49). The vertical dashed line represents the median progression-free survival (5.6 months). The stars represent patients achieving RECIST objective responses. The arrows represent patients non-progressing in the last central radiological assessment. RECIST, Response Evaluation Criteria in Solid Tumors.
Figure 3 Progression-free survival to treatment by patient, based on RECIST central radiological assessment. Each patient in the efficacy population in phase II is represented as bars (n=49). The vertical dashed line represents the median progression-free survival (5.6 months). The stars represent patients achieving RECIST objective responses. The arrows represent patients non-progressing in the last central radiological assessment. RECIST, Response Evaluation Criteria in Solid Tumors.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 188

Metadata

Authors
Martin-Broto, J., Hindi, N., Grignani, G., Martinez-Trufero, J., Redondo, A., Valverde, C., Stacchiotti, S., Lopez-Pousa, A., D'Ambrosio, L., Gutierrez, A., Perez-Vega, H., Encinas-Tobajas, V., de Alava, E., Collini, P., Peña-Chilet, M., Dopazo, J., Carrasco-Garcia, I., Lopez-Alvarez, M., Moura, D. S., & Lopez-Martin, J. A.
Affiliations
  • Medical Oncology Department, University Hospital Virgen del Rocio, Sevilla, Spain
  • Instituto de Biomedicina de Sevilla (ES)
  • Candiolo Cancer Institute (IT)
  • Medical Oncology Department, Miguel Servet University Hospital, Zaragoza, Spain
  • Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain
  • Vall d'Hebron Hospital Universitari (ES)
  • Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
  • Medical Oncology Department, Sant Pau Hospital, Barcelona, Spain
  • Division of Medical Oncology, Candiolo Cancer Institute, FPO - IRCCS - Str. Prov.le 142, km. 3,95 - Candiolo (TO) 10060, Candiolo, Italy
  • Hospital Universitario Son Espases (ES)
  • Radiology Department, University Hospital Virgen del Rocio, Sevilla, Spain
  • Hospital Universitario Virgen del Rocío (ES)
  • Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocio University Hospital /CSIC/University of Sevilla/CIBERONC, Sevilla, Spain
  • Istituti di Ricovero e Cura a Carattere Scientifico (IT)
  • Institute of Biomedicine of Sevilla (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain
  • Research Institute Hospital 12 de Octubre (ES)
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2020-11
Volume
8
Issue
2
Pages
e001561
ISSN
2051-1426 (ISSN-L)
OpenAlex
W3100757401
Cited by
183
References
35
Citations by year
2026: 18 · 2025: 37 · 2024: 37 · 2023: 36 · 2022: 34 · 2021: 20 · 2020: 1
FWCI
13.53
Type
journal article
Language
en
Open access
Locations
  • Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by-nc)
  • Hispana (submittedVersion, cc-by-nc)
  • Deposito de Investigacion Universidad de Sevilla (University of Seville) (submittedVersion, cc-by)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion, cc-by-nc)
  • RISalud Institutional Health Repository of Andalucía (submittedVersion, cc-by-nc)
  • DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion, cc-by-nc)
Funders
Beca Buesa (NA)
Topics
  • Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Vascular Tumors and Angiosarcomas
Keywords
nivolumab, sunitinib, soft tissue sarcoma, PD-1/PD-L1 blockade, angiogenesis inhibition, combination immunotherapy, tumor microenvironment, cold tumor conversion, progression-free survival, dose escalation, elevated liver enzymes, neutropenia
MeSH terms
Antineoplastic Agents, Immunological, Sunitinib, Nivolumab, Adult, Aged, Female, Humans, Male, Middle Aged, Sarcoma, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.